Detection of *Mycobacterium tuberculosis* in clinical sputum by a unique gene in MTB strains called Conserved protein TB18.5 (TB18.5)

Juanxiu Luo¹ | Xiaofei Li² | Yuzhu Song¹ | Hongwei Liu² | Kexi Zheng¹ | Xueshan Xia¹ | A-Mei Zhang¹ 

¹Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan, China  
²Department of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, Yunnan, China  

**Abstract**

A rapid and accurate diagnosis increases the treatment effect and decreases the mortality of tuberculosis (TB) patients. The purpose of this study was to establish an accurate, unique, and rapid molecular diagnostic technique to screen *Mycobacterium tuberculosis* (MTB) from clinical sputum. A unique gene in MTB strains called conserved protein TB18.5 (TB18.5) was selected by bioinformatics analysis. Two pairs of primers were designed to amplify TB18.5 using the nested polymerase chain reaction (PCR) or quantitative real-time PCR. Nine pathogens and the MTB strain were used to determine the specificity of the TB18.5 gene. The sensitivity assay was performed after optimizing the PCR conditions. The correct fragment was amplified when a 10 copy number template was used. A total of 232 sputum samples were collected from TB patients (from 2019 to 2020) to evaluate the accuracy of the molecular method in this study. MTB was first detected using the BACTEC MGIT-960 culture test and the Gene Xpert MTB/RIF assay. Totals of 195 (84.05%), 182 (78.45%), and 162 (69.83%) sputum samples were determined to be infected with MTB using nested PCR, the Gene Xpert MTB/RIF assay, and the BACTEC MGIT-960 culture test, respectively. In summary, a rapid, unique, and sensitive molecular method was established to diagnose TB infection in clinical sputum samples.

**KEYWORDS**  
conserved protein TB18.5, *Mycobacterium tuberculosis*, sensitivity, specificity, sputum

1 | INTRODUCTION

Tuberculosis (TB) is a common infectious disease caused by *Mycobacterium tuberculosis* (MTB). The main organ infected by MTB is the lung, but many other tissues or organs can be affected, such as the bone and pleura.¹ MTB is mainly transmitted by cough or sneeze droplets,² so protecting against TB in the clinic is difficult. Although the Bacillus Calmette-Guérin vaccine and anti-TB drugs are widely used in many countries, approximately ten million people developed TB in 2017, and about 40% of these TB patients lived in South East Asia.³⁻⁵ Two million people die of MTB infection each year due to poor quality of life and lack of awareness.⁶ China is one of
30 high-burden countries for TB disease and experiences one million new TB cases and 130,000 deaths annually. The number of TB patients has increased recently, and most infections occur in patients with human immunodeficiency virus (HIV) infection. Moreover, TB is the first cause of death from infection with a single agent.

An early and accurate diagnosis of TB is the critical factor for controlling and effectively treating the epidemic. Molecular detection, sputum-smear microscopy, and culture-based methods are widely used to diagnose TB in the clinic. The benefits of molecular diagnosis are rapidity, specificity, and high sensitivity. The Xpert MTB/RIF assay has been recommended and promoted as the molecular criterion for diagnosing TB by the World Health Organization (WHO). However, due to its high cost, the Xpert MTB/RIF assay cannot be widely used in some regions.

In this study, a specific gene called conserved protein TB18.5 (TB18.5) was selected to detect MTB using the nested polymerase chain reaction (PCR) or quantitative real-time PCR (qRT-PCR). The specificity and sensitivity of this molecular method were determined to be high after optimizing the PCR conditions.

2 MATERIALS AND METHODS

2.1 Collection and DNA extraction of clinical sputum

A total of 232 clinical sputum samples were collected from TB patients by physicians at Kunming Third People Hospital from January 2019 to December 2020. About 1 ml of sputum was obtained from each patient and liquefied using N-acetyl-L-cysteine and sodium hydroxide (NZLC-NaOH) (ratio = 2:1). The samples were incubated at 37°C and 200 r/min for 30 min, followed by centrifugation of the liquefied sputum at 10,625 g for 30 min, to obtain the precipitate. Genomic DNA of each sample was extracted using the G+ Bacteria Genomic DNA Kit (ZomanBio, Beijing, China) according to the manufacturer’s instructions.

Written informed consent was obtained from all patients before the study, which conformed to the tenets of the Declaration of Helsinki. This study was approved by the Institutional Review Board of Kunming University of Science and Technology (Approval No. 2014SK027). All experiments were performed following relevant guidelines and regulations.

2.2 BACTEC MGIT-960 CULTURE test and the Gene Xpert MTB/RIF assay

Sputum from all patients was subjected to the BACT MGIT-960 test and Gene Xpert MTB/RIF assay at Kunming Third People’s Hospital. The sputum was liquefied using NZLC-NaOH (2:1) before the BACT MGIT-960 test (Becton-Dickinson, Brea, CA, USA). Fluorescence intensity was tested to evaluate MTB positivity. A 192-bp region of the rpoB gene was amplified and detected using GeneXpert (Cepheid, Sunnyvale, CA, USA).

2.3 Selection of specific genes and primer design

A total of 173 genome sequences of Mycobacterium were downloaded and analyzed. A specific MTB gene was selected using the method from our previous study. Briefly, 173 genomes of Mycobacterium (including 10 MTB sequences) were downloaded from the NCBI to a local database and blasted using BLAST software. The potential specific genes were further blasted using online BLAST at the NCBI. Finally, the TB18.5 gene was considered a specific gene of the MTB strains. TB18.5 primers were designed for further study.

2.4 Nested PCR amplification

One-step PCR was performed in a 20 µl reaction volume, including 3 µL of DNA extracted from sputum, 10 µL of 2× TSINGKE Master Mix, and 0.3 µM each of the myco-F1 and myco-R1 primers. The PCR conditions for the first step were one cycle of 94°C for 5 min, 25 cycles of 94°C for 30 s, 57.5°C for 30 s, 72°C for 40 s, and one extension cycle of 72°C for 5 min. Nested PCR was also performed in a 20 µl reaction volume, including 3 µl of the amplicon from the first-step PCR, 10 µL of 2× TSINGKETM Master Mix (or 2× ChamQ SYBR qPCR Master Mix [Vazyme, Beijing, China] for qRT-PCR), and 0.3 µM of each of the myco-F2 and myco-R2 primers. The PCR conditions were one cycle of 94°C for 5 min, 25 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for 10 s, and one extension cycle of 72°C for 5 min.

2.5 Specificity and sensitivity testing

Six common clinical pathogens (Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus haemolyticus, and Acinetobacter baumannii) and three other Mycobacterium species (Mycobacterium avium, Mycobacterium chelonei, and Mycobacterium intracellulare) were used as negative controls to investigate the specificity of the TB18.5 gene and the primers. The TB18.5 gene was constructed using the pMD 18-T vector (Takara, Shiga Japan) to test the sensitivity of the primers. Then, the plasmids were diluted to $10^6$, $10^5$, $10^4$, $10^3$, $10^2$, and $10^1$ copy numbers to achieve a sensitive assay.

2.6 Statistical analysis

The Pearson chi-square test with Yates’ correction was used to distinguish the statistical difference among results of three methods. The $p$-value <.05 was statistical significance. Statistical analysis was performed using GraphPad Prism 5 software (GraphPad Software Inc. USA).

3 RESULTS

The bioinformatics analysis revealed that the TB18.5 gene was considered a specific MTB gene. Two primer pairs were designed for nested PCR to amplify this gene in clinical samples (Table 1). To
test the specificity of the TB18.5 gene and the primers, nine common clinical pathogens and the MTB strain were amplified using the myco-F1/myco-R1 and myco-F2/myco-R2 primers. As shown in Figure 1, the MTB strain was successfully amplified by the two pairs of primers, but the other nine pathogens could not be amplified. Thus, the TB18.5 gene was highly specific to the MTB strain and could be used to clinically diagnose TB patients.

The sensitivity of the molecular testing method was evaluated in this study using plasmids with $10^6$, $10^5$, $10^4$, $10^3$, $10^2$, and $10^1$ copy numbers. The results showed that the amplicon band was clear when the plasmid with 10 copy numbers was used as the template (Figure 2). We tested primer sensitivity using qRT-PCR to directly observe the results. The melting curve was detected when the template was a plasmid with 10 copy numbers (Figure 3). All 232 sputum samples from TB patients were tested using the BACTEC MGIT-960 CULTURE test, the Gene Xpert MTB/RIF assay, and nested PCR in this study. The results showed that 195 (84.05%), 182 (78.45%), and 162 (69.83%) samples were identified as MTB using nested PCR, the Gene Xpert MTB/RIF assay, and the BACTEC MGIT-960 CULTURE test, respectively. Although the nested PCR-positive ratio was the highest among the three methods, no statistical difference was identified between results of nested PCR and Gene Xpert MTB/RIF assay. However, the $P$-value showed significant difference between results of BACTEC MGIT-960 CULTURE test and nested PCR ($p = 0.0004$)/ or Gene Xpert MTB/RIF assay ($p = 0.044$).

### TABLE 1 Information of nested PCR primers

| primer     | Sequence (5′–3′)                                      | Amplicon size (bp) |
|------------|------------------------------------------------------|-------------------|
| Myco-F1    | ATGACGGCAATCTCGTGCTCA                                 | 481               |
| Myco-R1    | TTAGCTGGCCGCCAGCTGCTCG                                 |                   |
| Myco-F2    | GCAAGACCGTCAGGTCACC                                   | 375               |
| Myco-R2    | CCAGGACGTGTGAGCAGCA                                   |                   |

**FIGURE 1** Evaluating specificity of the conserved protein TB18.5 gene in MTB. Bands 1–6 are amplification with template *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Staphylococcus haemolyticus*, and *Acinetobacter baumannii*, respectively. Bands 8–11 are amplification with template *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium chelonae*, and *Mycobacterium intracellulare*. M means DNA marker DL2000; NC means negative control.

### 4 DISCUSSION

TB is one of the top ten causes of death in the world, and also causes high morbidity in poor regions or HIV-positive patients. Although TB vaccines and drugs have been widely used to control MTB infections, many patients develop TB each year. Although the WHO has proposed to eliminate TB by 2035, it will be difficult to accomplish this task. An early and rapid diagnosis of TB patients could increase the treatment effect and decrease the chances for drug-resistant TB.

Molecular detection, sputum-smear microscopy, and culture-based methods are generally used to diagnose TB. Sputum-smear microscopy is currently recommended for regular detection and is performed using an acid-fast staining microscopic examination. Although this method was invented more than 100 years ago, it is still widely used in clinics because of its high speed and low price. However, the lower specificity and sensitivity of sputum-smear microscopy can lead to false-positive or false-negative results. Fluorescence microscopy increases the sensitivity but not the specificity of sputum-smear microscopy; therefore, it is used as a preliminary evaluation of MTB infection. MTB culture is the golden standard to diagnose TB, but it is time-consuming. Although the BACTEC MGIT-960 CULTURE test shortened the MTB culture time, 1 week is required to obtain the results. Thus, molecular detection of MTB is an accurate and rapid method compared with phenotypic methods. The Xpert MTB/RIF assay was first recommended by the WHO in 2010 to diagnose pulmonary TB disease in adults and was considered to complement proportional methods, but this method requires expensive equipment. A simple and lower-cost molecular method, similar to the LCD-array used in testing drug-resistant mutations, should be established to apply in developing countries.

To establish a rapid, sensitive, and specific molecular method to detect MTB, a unique MTB gene (TB18.5) was selected and primers were designed for nested PCR (or nested RT-PCR). Then, the specificity and sensitivity of this method were determined. After analyzing the results of the Xpert MTB/RIF assay, the BACTEC MGIT-960 CULTURE test, and the molecular method in this study, the positive rate was higher using the established molecular method than the other two methods. Moreover, the low cost, high accuracy, specificity, and sensitivity suggested that the molecular method could be used in the clinic or laboratory in the future.
Although high detection ratio of nested PCR was identified, there were still a few limitations. Firstly, the numbers of bacteria used for testing the specificity of nested PCR were less, so we should collect more kinds of bacteria to further identify its specificity. Secondly, whether this nested PCR method could refer to the other kind of TB samples (such as ascites and synovial fluid) was not clear. Finally, we should improve protocol of sample preparation to increase the positive detection ratio of the nest-PCR method.

In summary, the TB18.5 gene, which was identified as a unique gene in MTB strains, was used to evaluate MTB infections. The optimized nested PCR/nested qRT-PCR method was established to detect MTB in clinical sputum samples, which showed higher positive ratio than Xpert MTB/RIF assay and the BACTEC MGIT-960 CULTURE test. Thus, it is benefit for TB patients to obtain early and sensitively diagnose and treatment by using this nest-PCR method.

ACKNOWLEDGMENTS
We thank all the participants for providing the sputa samples in this study. This study was supported by Leading Reserve Talents of Academy and Science and Technology in Yunnan Province (2019HB002), Yunnan Ten Thousand Talents Plan Young & Elite Talents Project and Major Science and Technology Projects (Biomedicine) Projects (2019ZF004).

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
AMZ, YZS, and XSX designed the experiments. JXL and KXZ performed the experiments. AMZ, JXL, and YZS analyzed the data and prepared for the article. XFL and HWL collected the sputa samples and performed the clinical evaluation.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID
A-Mei Zhang https://orcid.org/0000-0002-6681-3376

REFERENCES
1. Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary tuberculosis: pathophysiology and imaging findings. Radiographics. 2019;39(7):2023-2037.
2. Jeffries C, Lobue P, Chorba T, Metchock B, Kashef I. Role of the health department in tuberculosis prevention and control-legal and public health considerations. Microbiol Spectrum. 2017;5(2). https://doi.org/10.1128/microbiolspec.TNMI7-0034-2016
3. Miyazaki J, Onozawa M, Takaoka E, Yano I. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer. Int J Urol. 2018;25(5):405-413.

4. Tang J, Yam WC, Chen Z. Mycobacterium tuberculosis infection and vaccine development. Tuberculosis (Edinburgh, Scotland). 2016;98:30-41.

5. World Health Organization. Global Tuberculosis Report 2019. World Health Organization; 2019.

6. Khan MK, Islam MN, Ferdous J, Alam MM. An Overview on Epidemiology of tuberculosis. Mymensingh Med J. 2019;28(1):259-266.

7. Gupta S, Kakkar V. Recent technological advancements in tuberculosis diagnostics - A review. Biosens Bioelectron. 2018;115:14-29.

8. Wilson ML. Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing. Arch Pathol Lab Med. 2013;137(6):812-819.

9. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J. 2013;42(1):252-271.

10. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570-581.

11. Khan MK, Islam MN, Ferdous J, Alam MM. An Overview on Epidemiology of tuberculosis. Mymensingh Med J. 2019;28(1):259-266.

12. Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642-1656.

13. Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018;6(4):299-314.

14. Uplekar M, Weil D, Lonroth K, et al. WHO's new end TB strategy. Lancet (London, England). 2015;385(9979):1799-1801.

15. May K, Marchand-Austin A, Peci A, Jamieson FB. A method for improved fluorescent staining for acid fast microscopy by incorporating an acetone rinse step. Diagn Microbiol Infect Dis. 2019;93(4):329-333.

16. Mohajeri P, Moradi S, Atashi S, Farahani A. Mycobacterium tuberculosis Beijing Genotype in Western Iran: distribution and drug resistance. J Clin Diagn Res. 2016;10(10):OC05-OC07.

17. Yeh J. Validation of a model for predicting smear-positive active pulmonary tuberculosis in patients with initial acid-fast bacilli smear-negative sputum. Eur Radiol. 2018;28(1):243-256.

18. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet. 2010;375(9729):1920-1937.

19. WHO. Who Guidelines Approved by the Guidelines Review Committee. In Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. World Health Organization; 2011.

20. Atashi S, Izadi B, Jalili S, Madani SH, Farahani A, Mohajeri P. Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and northwest Iran. New Microbes New Infect. 2017;19:117-120.

21. Mohajeri P, Sadri H, Farahani A, Noroozi B, Atashi S. Frequency of mutations associated with rifampicin resistance in Mycobacterium tuberculosis strains isolated from patients in west of Iran. Microb Drug Resist. 2015;21(3):315-319.

How to cite this article: Luo J, Li X, Song Y, et al. Detection of Mycobacterium tuberculosis in clinical sputum by a unique gene in MTB strains called Conserved protein TB18.5 (TB18.5). J Clin Lab Anal. 2021;35:e24033. https://doi.org/10.1002/jcla.24033